CD7-specific CAR-T Cell therapy(Taihe Chunyu Biotechnology)

N/A

Report date: 2024/12/09 20:01:07

Base Information

Drug NameCD7-specific CAR-T Cell therapy(Taihe Chunyu Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD7T lymphocyte replacements
TargetsT-cell antigen CD7
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, T-CellLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHebei Tahoe Chunyu Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Tahoe Chunyu Biotechnology Co LtdZhengzhou University
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, T-CellLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A